indazoles has been researched along with Neoplasms, Cystic, Mucinous, and Serous in 2 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 1 (50.00) | 24.3611 |
2020's | 1 (50.00) | 2.80 |
Authors | Studies |
---|---|
Bartlett, DL; Choudry, HA; Dilly, A; Honick, BD; Lee, YJ | 1 |
Dinkic, C; Eichbaum, M; Fricke, HC; Gebauer, G; Grischke, EM; Lenz, F; Marme, F; Rom, J; Schmidt, M; Schneeweiss, A; Sohn, C; Wallwiener, M | 1 |
1 trial(s) available for indazoles and Neoplasms, Cystic, Mucinous, and Serous
Article | Year |
---|---|
Pazopanib (GW786034) and cyclophosphamide in patients with platinum-resistant, recurrent, pre-treated ovarian cancer - Results of the PACOVAR-trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Ovarian Epithelial; Cyclophosphamide; Diarrhea; Disease-Free Survival; Drug Resistance, Neoplasm; Fatigue; Female; Humans; Indazoles; Leukopenia; Liver Function Tests; Maximum Tolerated Dose; Middle Aged; Neoplasm Grading; Neoplasm Recurrence, Local; Neoplasms, Cystic, Mucinous, and Serous; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Platinum Compounds; Pyrimidines; Sulfonamides | 2017 |
1 other study(ies) available for indazoles and Neoplasms, Cystic, Mucinous, and Serous
Article | Year |
---|---|
Rational application of targeted therapeutics in mucinous colon/appendix cancers with positive predictive factors.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Appendiceal Neoplasms; Appendix; Cell Line, Tumor; Chemotherapy, Adjuvant; Colon; Colonic Neoplasms; Drug Synergism; Endoplasmic Reticulum Chaperone BiP; Female; Humans; Indazoles; Intestinal Mucosa; Mice; Mitogen-Activated Protein Kinase Kinases; Molecular Targeted Therapy; Mucin-2; Mutation; Neoplasms, Cystic, Mucinous, and Serous; Phosphatidylinositol 3-Kinases; Primary Cell Culture; Protein Kinase Inhibitors; Proto-Oncogene Proteins p21(ras); Pyridones; Pyrimidinones; Sulfonamides; Xenograft Model Antitumor Assays | 2020 |